---
source_url: https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/post-myocardial_infarction
content_type: therapeutic_choices
document_id: post-myocardial_infarction
source_system: CPS (Canadian Pharmacists Association)
processed_at: '2025-05-29T07:19:41.247888Z'
processing_stage: url_preservation_final
pipeline_version: '1.0'
download_date: unknown
converted_from: post-myocardial_infarction.html
redownload_instructions:
  method: Use unified downloader
  command: python cps_unified_downloader.py --types therapeutic_choices
  note: Requires valid CPS access credentials
---

# Post-myocardial Infarction

### Post-myocardial Infarction

|  |
| --- |
| Derek Y.F. So, MD, FRCPC, FACC |
| Date of Revision: June 3, 2021 |
| Peer Review Date: March 1, 2020 |


#### Introduction

The term post-myocardial infarction applies to patients who have experienced either ST elevation myocardial infarction (STEMI) or non‚ÄìST elevation myocardial infarction (NSTEMI). While the early management differs, the long-term therapeutic goals are similar: returning patients to an ideal quality of life and preventing progression of disease and repeat infarction. For details on early management, see Acute Coronary Syndromes.

For patients with STEMI, initial acute reperfusion strategies consisting of primary percutaneous coronary intervention (PCI) or thrombolytic therapy enable restoration of patency to the occluded culprit artery and offer improved prognosis compared to patients treated conservatively.‚Äã[^[1]] Primary PCI, with reperfusion to the culprit artery, should be the first-line therapy if it can be done in an expedient manner. In addition, angiography at primary PCI enables evaluation of the non-culprit arteries and preliminary assessment of left ventricular function. For those receiving thrombolytic therapy, early assessment of reperfusion success is imperative, as transfer for urgent angiography is indicated for failed reperfusion.‚Äã[^[2]]‚Äã[^[3]] Evidence suggests the need for early cardiac catheterization, even among those with successful reperfusion.‚Äã[^[4]] This is especially evident in individuals with large infarcts, where a pharmacoinvasive approach (transfer for angiography immediately after thrombolysis) prevents subsequent recurrent ischemia and infarction and allows early risk stratification.‚Äã[^[5]]‚Äã[^[6]] While STEMI requires more urgent upfront treatment, NSTEMI actually has higher long-term morbidity and mortality.‚Äã[^[7]] Accordingly, the need for risk stratification early after NSTEMI is essential. An ‚Äúinvasive approach‚Äù of early angiography with subsequent revascularization with PCI or coronary bypass surgery has been shown to reduce recurrent morbidity and mortality in high-risk NSTEMI patients.‚Äã[^[8]]

#### Goals of Therapy



#### Investigations





#### Therapeutic Choices

#### Nonpharmacologic Choices



#### Pharmacologic Choices

After MI, patients are at substantial risk for subsequent major adverse cardiovascular events (MACE), such as nonfatal MI, death or stroke. Secondary prevention with several classes of drugs independently reduces incidence of MACE by approximately 25%‚Äã[^[13]] (see Table 1). An overview of individual agents is provided in Table 2.

| Drug Therapy | Relative Risk Reduction | 2-Year Event Rate(death, MI or stroke) |
| --- | --- | --- |
| None | ‚Äî | 8% |
| ASA | 25% | 6% |
| Beta-blocker | 25% | 4.5% |
| Lipid lowering(reduce LDL-C by 1.5 mmol/L) | 30% | 3% |
| ACE inhibitor | 25% | 2.3% |
| Cumulative relative risk reduction if all 4 drugs are used | ‚âà75% |  |
| To calculate the cumulative risk reduction, a multiplicative scale was used. For example, 2 interventions, each reducing the risk of an event by 30%, would be expected to have about a 50% relative risk reduction (1 ‚Äì [0.7 √ó 0.7]). No interactions in treatment effects were observed in trials, suggesting that the proportionate risk reduction of a specific drug in the presence or absence of other effective interventions would be expected to be similar. Smoking cessation lowers the risk of recurrent MI by about half after 2 years. In a smoker with vascular disease, quitting smoking and the use of the 4 preventive strategies could theoretically have a large potential benefit (approximately 80% relative risk reduction). |  |  |


Reprinted from Yusuf S. Two decades of progress in preventing vascular disease. *Lancet* 2002;360(9326):2-3. Copyright 2002. With permission from Elsevier.

#### Antiplatelet Agents

Myocardial infarction is a consequence of an acute plaque rupture, in which activated platelets play an integral role. Consequently, after reperfusion therapy, early inhibition of platelets with ASA and an adenosine P2Y12 receptor inhibitor is required to maintain vessel patency and prevent reinfarction.‚Äã[^[14]] Dual antiplatelet therapy (DAPT) is also required for prevention of acute occlusion of stents after PCI‚Äã[^[15]]‚Äã[^[16]] or in patients managed medically.‚Äã[^[17]] Long-term antiplatelet therapy is effective in preventing MACE.‚Äã[^[10]] Currently available P2Y12 inhibitory drugs include the thienopyridines (clopidogrel, prasugrel) and ticagrelor.

In patients who have received thrombolytic therapy for acute MI, clopidogrel or ticagrelor (if patient <75 y) can be used as part of dual antiplatelet therapy with ASA.‚Äã[^[17]]‚Äã[^[18]] For most other infarct patients, the first-line P2Y12 inhibitor is either prasugrel or ticagrelor.‚Äã[^[19]]‚Äã[^[20]]

Irrespective of the choice of P2Y12 inhibitor, the duration of dual antiplatelet therapy should be at least 1 year after MI in patients with low bleeding risk.‚Äã[^[21]] Evidence suggests that in some patients, there may benefit from prolonging DAPT post-MI for up to 3 years beyond the first year. In the PEGASUS-TIMI 54 trial, cardiovascular benefit was shown from using a ticagrelor dose of 60 mg twice daily.‚Äã[^[22]] Data from the DAPT trial also suggests benefit of long-term therapy among higher-risk patients treated with clopidogrel or prasugrel.‚Äã[^[23]] The DAPT Risk Calculator may be used to select patients most likely to benefit from continuation of their P2Y12 inhibitor;‚Äã[^[24]]‚Äã[^[25]] however, this has to be weighed carefully against bleeding risk. In certain patients, e.g., those at a high risk of bleeding, earlier discontinuation of the P2Y12 inhibitor might be considered in consultation with the cardiologist. For other patients, high-risk anatomical or PCI features may dictate consideration for long-term dual antiplatelet therapy.

Another strategy to consider at 1 year is a combination of rivaroxaban 2.5 mg twice daily with low dose aspirin at 81 mg. This combination was shown to be of benefit in the COMPASS study among patients with stable coronary disease.‚Äã[^[26]] This may specifically benefit patients also known to have peripheral vascular disease, or those considered at higher risk of stroke rather than MI.

#### Acetylsalicylic acid

ASA is the antiplatelet agent of choice for long-term secondary prevention due to its effectiveness and low cost. Indefinite therapy is indicated in all postinfarct patients; low-dose therapy (75‚Äì100 mg) is as effective as higher doses (300‚Äì325 mg).‚Äã[^[27]] Low-dose ASA is generally better tolerated, with lower bleeding risk.‚Äã[^[28]] ASA is used in combination with a P2Y12 inhibitor when indicated (see Figure 1).

#### Clopidogrel

The thienopyridine clopidogrel continues to be commonly used after PCI. In MI patients receiving clopidogrel after PCI, a dose of 150 mg daily for the first 6 days has been shown to be superior and should be considered.‚Äã[^[17]]‚Äã[^[29]] A daily dose of 75 mg should be used after the initial 6 days of high-dose therapy or for those patients deemed not to require the initial high-dose therapy. For patients with ASA allergy, chronic clopidogrel therapy may be a substitute.

#### Prasugrel

Prasugrel is a thienopyridine with an active metabolite that binds irreversibly to the P2Y12 receptor. Prasugrel has a faster onset of action with increased potency in platelet inhibition compared to clopidogrel. In patients with MI undergoing PCI, prasugrel reduced MACE (2.2% absolute risk reduction [ARR]) compared to clopidogrel.‚Äã[^[19]] Current guidelines suggest prasugrel or ticagrelor as first-line agents after NSTEMI or STEMI.‚Äã[^[17]]‚Äã[^[30]] Increased bleeding has been associated with prasugrel among patients who are elderly (>75 y), have a history of stroke or TIA, or who have low body weight (<60 kg). Accordingly, guidelines suggest a reduced dose of prasugrel in patients ‚â•75 years of age or who weigh ‚â§60 kg.‚Äã[^[17]] Prasugrel should be avoided in patients with previous stroke or TIA.¬†

#### Ticagrelor

Ticagrelor, a cyclopentyl triazolopyrimidine, is a direct, reversible inhibitor of the P2Y12 receptor. It is more effective (1.9% ARR in death from vascular causes, MI or stroke) in acute coronary syndrome when compared to clopidogrel.‚Äã[^[20]] Ticagrelor is endorsed as first-line therapy in current guidelines.‚Äã[^[17]]‚Äã[^[30]] Bleeding is increased among patients treated medically or with PCI when compared to clopidogrel.‚Äã[^[20]] Dyspnea may occur in approximately 14% of patients treated with ticagrelor.‚Äã[^[20]] 

#### Beta-Blockers

In the absence of contraindications, consider this class of medication in all patients after STEMI or NSTEMI, as they have been proven to reduce MACE postinfarct.‚Äã[^[10]]‚Äã[^[30]] In particular, beta-blockers play a role in the reduction of reinfarction and prevention of ventricular arrhythmia in the early phase after infarction.‚Äã[^[31]] Beta-blockers should be started within a few days of infarction and dosage titrated to achieve a heart rate <70 bpm. However, IV beta-blockers should be used cautiously in the early acute phase, as they may contribute to hemodynamic instability in patients suffering large infarcts.‚Äã[^[31]] Avoid beta-blockers in patients with hypotension, bradycardia and active heart failure. Patients with reduced LV function derive significant benefit from beta-blockers, but should be monitored closely, especially in the postinfarction period. This benefit extends to those already treated with ACE inhibitors. Beta-blockers can be stopped if side effects are present and if LV function is normal. They should be continued indefinitely in patients with LV dysfunction.

#### Inhibition of the Renin-Angiotensin-Aldosterone Pathway

#### ACE Inhibitors

ACE inhibitors should be considered in all post-MI patients, especially in those with LV dysfunction (LVEF <40%), hypertension or diabetes mellitus.‚Äã[^[10]]‚Äã[^[30]] The relative benefits of ACE inhibitors are greater among those with LV dysfunction, as they play a role in LV remodelling post-MI. Long-term treatment with ACE inhibitors reduces cardiovascular death and MI among those with atherosclerosis and multiple risk factors.‚Äã[^[32]] In patients with significant renal dysfunction or hyperkalemia, avoid ACE inhibitors.‚Äã[^[10]] Titration to evidence-based dosages (see Table 2) is important and should be evaluated at follow-up visits.‚Äã[^[32]]‚Äã[^[33]] The development of a dry cough may require some patients to discontinue ACE inhibitors.

#### ARBs

ARBs may be used instead of ACE inhibitors in those intolerant of the latter because of cough. In a randomized control study, valsartan demonstrated equivalent benefit to captopril among post-MI patients with heart failure and LV dysfunction.‚Äã[^[34]] Combination therapy with an ACE inhibitor and an ARB increases adverse events and has no evidence of benefit.‚Äã[^[35]]

#### Mineralocorticoid Receptor Antagonists

Consider using a mineralocorticoid receptor antagonist (aldosterone antagonist) in patients post-MI with significant LV dysfunction (EF ‚â§40%). Eplerenone, when added to other post-MI evidenced-based therapies, has demonstrated a reduction in mortality and hospitalization for cardiovascular events (heart failure, re-infarction, stroke, ventricular arrhythmia).‚Äã[^[36]] Similarly, spironolactone has been proven beneficial in patients with severe LV dysfunction when used in conjunction with an ACE inhibitor and a diuretic.‚Äã[^[37]] Comparative data are limited, so choice is based on tolerability and availability. Closely monitor electrolytes, as eplerenone and spironolactone are associated with a risk of hyperkalemia. 

#### HMG-CoA Reductase Inhibitors (Statins)

Starting a statin early after MI decreases both early and late adverse events. Guidelines suggest documenting the cholesterol profile within 24 hours of infarction, as LDL cholesterol may be falsely low for up to 4 weeks postinfarction.‚Äã[^[30]]‚Äã[^[38]] Evidence suggests that intensive treatment with higher-dose statins (e.g., atorvastatin 80 mg/day or rosuvastatin 40 mg/day) early after MI confers additional benefits compared with moderate dosages.‚Äã[^[39]] The benefit of statins extends beyond lowering of LDL cholesterol levels alone as they contribute to plaque stabilization by preventing future acute coronary syndromes.‚Äã[^[40]]

Indefinite continuation of statin therapy is integral to the prevention of ischemic events. Following MI, all patients are considered to be in the high-risk group for subsequent events.‚Äã[^[41]] Current Canadian Cardiovascular Society guidelines advocate a minimum target LDL-C of <1.8 mmol/L.‚Äã[^[41]] Muscle-related intolerance may be confirmed in up to 6% of patients.‚Äã[^[42]] In patients intolerant of statins, alternative cholesterol-lowering agents such as ezetimibe or PCSK9 inhibitors may be considered (see Dyslipidemias). 

#### Oral Anticoagulants

Oral anticoagulants are recommended in post-MI patients with paroxysmal or persistent atrial fibrillation or demonstrable LV thrombus (see Figure 2 and Figure 3).‚Äã[^[10]] Warfarin continues to be the oral anticoagulant of choice for patients with LV thrombus due to lack of evidence with direct-acting oral anticoagulants (DOACs) for this indication. DOACs should be the oral anticoagulant of choice for patients with atrial fibrillation when used with a P2Y12 inhibitor.‚Äã[^[45]]‚Äã[^[46]]‚Äã[^[47]]‚Äã[^[48]] In patients requiring a DOAC, consider early discontinuation of ASA, from as early as 1 day and up to 6 months after PCI.‚Äã[^[49]]

There is a significant increase in bleeding risk when warfarin is used concurrently with dual antiplatelet therapy.‚Äã[^[30]] This is of concern when combining prasugrel or ticagrelor with warfarin as there may be an even higher risk of bleeding compared to clopidogrel.‚Äã[^[43]] Accordingly, most patients receiving warfarin should use clopidogrel as the P2Y12 inhibitory drug. ASA should be discontinued early. Close monitoring of INR in these patients is imperative, with consideration of shorter duration of antiplatelet therapy if indefinite warfarin therapy is indicated. In those treated with warfarin for LV thrombus post-MI, a repeat echocardiography should be performed after 3 months of treatment.‚Äã[^[10]] If the thrombus has resolved, consider discontinuation of warfarin therapy. 



Guidelines suggest that DOACs might be considered as an alternative to warfarin when an anticoagulant and antiplatelet agent are used together.‚Äã[^[30]]‚Äã[^[50]]‚Äã[^[51]] In this situation, consider stopping ASA early (as early as day 1 or up to 6 months after PCI) with clopidogrel continued at the discretion of the treating physician.‚Äã[^[49]]‚Äã[^[50]] Experience with prasugrel or ticagrelor is limited at this point, so they are best avoided.‚Äã[^[49]]‚Äã[^[50]] Decision on a regimen should be individualized for each patient after consultation with the treating cardiologists.

#### Choices during Pregnancy and Breastfeeding

#### Post-myocardial Infarction and Pregnancy

Myocardial infarction during the peripartum period is rare. However, if MI occurs in the peripartum period, a diagnosis of spontaneous coronary artery dissection (SCAD) should be considered as it is the most common cause of MI in pregnancy.‚Äã[^[52]] Risk factors for SCAD in pregnancy include multiparous, use of infertility therapies and pre-eclampsia.‚Äã[^[52]] In the largest registry of patients with SCAD, 4.7% of cases occurred during the peripartum period and 2.9% during breastfeeding.‚Äã[^[53]]

#### Management

SCAD is diagnosed with angiography, with the majority of these patients managed conservatively with medications rather than PCI or surgery. DAPT may confer some benefit in patients with SCAD, based on the presumed prothrombotic nature of intimal tears.‚Äã[^[54]] Beta-blockers similarly may provide benefit by reduction in shear stress. ACE inhibitors may be considered if there is significant LV dysfunction (‚â§40%). Statins would not be indicated in patients with SCAD, unless concurrent CAD is documented.

#### Post-myocardial Infarction and Breastfeeding

There has been concerning documentation of the onset of SCAD symptoms during lactation;‚Äã[^[52]] accordingly, continuation of breastfeeding should be done with careful consideration. For those with CAD rather than SCAD as a cause for MI, ASA and beta-blockers can be used at low doses in breastfeeding patients. However, if P2Y12 inhibitors, ACE inhibitors or statins are used, breastfeeding would not be recommended.

A discussion of general principles on the use of medications in these special populations can be found in Drugs Use during Pregnancy and Drug Use during Breastfeeding. Other specialized reference sources are also provided in these appendices.

#### Therapeutic Tips



#### Algorithms

![](images/postmyocardialinfarction_manposmyoinfpat.gif)


**AI Image Description:**
The image is a flowchart detailing the management of Acute Myocardial Infarction (AMI), specifically addressing STEMI (ST-Elevation Myocardial Infarction) and NSTEMI (Non-ST-Elevation Myocardial Infarction).

### Structure and Content:

1. **Acute Myocardial Infarction**
   - Divided into two categories: STEMI and NSTEMI.

2. **STEMI Management**
   - **Primary PCI (Percutaneous Coronary Intervention)**
   - **Thrombolytic Therapy**

3. **NSTEMI Management**
   - **Risk Stratification**: Consider cardiac catheterization for:
     - STEMI with nonreperfusion
     - Recurrent chest pain
     - LVEF (Left Ventricular Ejection Fraction) ‚â§ 40%
     - Hemodynamic instability
     - Most patients with NSTEMI
     - High-risk stress test

4. **Other Investigations**
   - Arrhythmia monitoring in the early post-infarction period
   - Assess size of infarction using LV angiogram, echo, or MUGA as indicated
   - Evaluate risk factors:
     - Blood glucose
     - BMI (Body Mass Index)
     - Cholesterol profile
     - Elevated blood pressure
     - Smoking

5. **Nonpharmacologic Management**
   - Rehabilitation programs:
     - Diet counseling/weight management
     - Exercise programs
     - Fitness for return to work
   - Address potential psychosocial issues, e.g., stress management, depression
   - Implantable defibrillator for patients with persistent diminished EF ‚â§ 30%

6. **Pharmacologic Management**
   - Dual antiplatelet therapy: ASA + P2Y12 receptor inhibitor
     - First-line: prasugrel/ticagrelor
     - Second-line: clopidogrel 150 mg daily for 3 days, then 75 mg daily
   - Beta-blockers, especially in patients with arrhythmias or LV dysfunction
   - ACE inhibitors for long-term vascular protection, especially important for those with LVEF ‚â§ 40%, hypertension, or diabetes
   - Statins: high dose is preferred post-infarction

### Notes:
- The flowchart provides a comprehensive approach to managing AMI, emphasizing both pharmacologic and nonpharmacologic strategies.
- It highlights the importance of risk stratification and continuous monitoring for effective treatment and recovery.

*AI-generated description for accessibility and content understanding*


angiotensin-converting enzyme

body mass index

ejection fraction

left ventricular

left ventricular ejection fraction

multiple-gated acquisition scan

non‚ÄìST segment elevation myocardial infarction

percutaneous coronary intervention

ST segment elevation myocardial infarction

![](images/postmyocardialinfarction_recpataf.gif)


**AI Image Description:**
The image is a medical flowchart for managing patients with atrial fibrillation (AF) undergoing elective percutaneous coronary intervention (PCI) without high-risk features. It outlines treatment strategies based on age and CHADS‚ÇÇ score.

### Flowchart Breakdown:

1. **Initial Condition:**
   - AF and elective PCI without high-risk features.

2. **Decision Point 1:**
   - **Criteria:** Age < 65 and CHADS‚ÇÇ = 0
     - **Treatment:** ASA (Aspirin) + Clopidogrel
     - **Duration:** At least 1 month for bare-metal stents (BMS) and at least 3 months for drug-eluting stents (DES), up to 12 months.
     - **Follow-up Treatment:** ASA ¬± P2Y‚ÇÅ‚ÇÇ inhibitor

3. **Decision Point 2:**
   - **Criteria:** Age ‚â• 65 or CHADS‚ÇÇ ‚â• 1
     - **Treatment:** OAC (Oral Anticoagulant) + Clopidogrel
     - **Duration:** At least 1 month for BMS and at least 3 months for DES, up to 12 months.
     - **Follow-up Treatment:** OAC ¬± SAPT (Single Antiplatelet Therapy)

### Notes:
- The flowchart provides guidance on antithrombotic therapy duration and combinations based on patient age and stroke risk (CHADS‚ÇÇ score).
- It distinguishes between different stent types (BMS and DES) and their respective treatment durations.
- The chart includes options for continuing therapy with either ASA or OAC, with or without additional antiplatelet agents.

*AI-generated description for accessibility and content understanding*


atrial fibrillation

acetylsalicylic acid

bare-metal stent

congestive heart failure, hypertension, age ‚â•75 years, diabetes mellitus, stroke (double weight)

drug-eluting stent

oral anticoagulant

percutaneous coronary intervention

single antiplatelet therapy

Reprinted from *Can J Cardiol*, 34(3), Mehta SR, Bainey KR, Cantor WJ et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy, 214-33, Copyright 2018, with permission from Elsevier.

![](images/postmyocardialinfarction_recpatafhigris.gif)


**AI Image Description:**
The image is a flowchart detailing the management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) or high-risk elective PCI. It outlines treatment strategies based on age and CHADS‚ÇÇ score.

### Flowchart Breakdown:

1. **Title**: AF and PCI for ACS or high-risk elective PCI

2. **Initial Decision Point**:
   - **Criteria**: 
     - Age < 65 and CHADS‚ÇÇ = 0
     - Age ‚â• 65 or CHADS‚ÇÇ ‚â• 1

3. **Left Branch (Age < 65 and CHADS‚ÇÇ = 0)**:
   - **Treatment**: ASA + P2Y‚ÇÅ‚ÇÇ inhibitor
     - **Details**: 
       - Ticagrelor or prasugrel preferred over clopidogrel for ACS
       - Duration after PCI: up to 12 months
   - **Follow-up**: ASA ¬± P2Y‚ÇÅ‚ÇÇ inhibitor

4. **Right Branch (Age ‚â• 65 or CHADS‚ÇÇ ‚â• 1)**:
   - **Treatment**: Reduced OAC + ASA + clopidogrel
     - **Details**:
       - ASA: stop 1 day post PCI or anytime up to 6 months
       - Followed by: clopidogrel + OAC
       - Duration after PCI: up to 12 months
   - **Follow-up**: OAC ¬± SAPT

### Notes:
- **a**: High-risk elective PCI
- **b**: CHADS‚ÇÇ score criteria
- **c**: P2Y‚ÇÅ‚ÇÇ inhibitor options
- **d**: Reduced OAC
- **e**: ASA stopping criteria
- **f**: Follow-up treatment
- **g**: OAC options

This flowchart provides a structured approach to antithrombotic therapy in patients with AF undergoing PCI, tailored to their age and stroke risk as assessed by the CHADS‚ÇÇ score.

*AI-generated description for accessibility and content understanding*


acute coronary syndrome

atrial fibrillation

acetylsalicylic acid

bare-metal stent

congestive heart failure, hypertension, age ‚â•75 years, diabetes mellitus, stroke (double weight)

drug-eluting stent

oral anticoagulant

percutaneous coronary intervention

single antiplatelet therapy

Reprinted from *Can J Cardiol*, 34(3), Mehta SR, Bainey KR, Cantor WJ et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy, 214-33, Copyright 2018, with permission from Elsevier.

#### Drug Table


**Drug Class: ACE Inhibitors‚Äã[b]**


**Drug Class: Angiotensin Receptor Blockers**


**Drug Class: Antiplatelet Agents**


**Drug Class: Beta1-adrenergic Antagonists, selective**


**Drug Class: Beta1-adrenergic Antagonists, selective with ISA**


**Drug Class: Beta1-adrenergic Antagonists with alpha1-blocking activity**


**Drug Class: HMG-CoA Reductase Inhibitors (Statins)**


**Drug Class: Mineralocorticoid Receptor Antagonists**

| Drug/‚ÄãCost[a] | Dosage | Adverse Effects | Drug Interactions | Comments |
| --- | --- | --- | --- | --- |
| **captopril** (generics) | Initial: 6.25 mg TID POTarget: 50 mg TID | Dry cough, hyperkalemia, angioedema (unusual).Can precipitate renal failure in patients with renovascular disease, volume depletion or in those receiving NSAIDs. | Marked increase in serum K‚Äã+ in patients receiving K‚Äã+ supplements and/or K‚Äã+-sparing diuretics.Reduced hypotensive effect and increased risk of renal dysfunction with NSAIDs.Elevated Li‚Äã+ levels (potential toxicity). | Use lower (i.e., 50%) initial doses in patients taking diuretics (increased risk of hypotension with hypovolemia).Hyperkalemia usually occurs only in patients taking K‚Äã+ supplements or drugs that cause K‚Äã+ retention, patients with renal impairment or those with diabetes and high normal serum K‚Äã+ levels. Assess SCr and K‚Äã+ after a few days, then regularly. |
| **cilazapril** (Inhibace, generics) | Initial: 0.5 mg daily POTarget in HF: 2.5‚Äì5 mg daily | Dry cough, hyperkalemia, angioedema (unusual).Can precipitate renal failure in patients with renovascular disease, volume depletion or in those receiving NSAIDs. | Marked increase in serum K‚Äã+ in patients receiving K‚Äã+ supplements and/or K‚Äã+-sparing diuretics.Reduced hypotensive effect and increased risk of renal dysfunction with NSAIDs.Elevated Li‚Äã+ levels (potential toxicity). | Use lower (i.e., 50%) initial doses in patients taking diuretics (increased risk of hypotension with hypovolemia).Hyperkalemia usually occurs only in patients taking K‚Äã+ supplements or drugs that cause K‚Äã+ retention, patients with renal impairment or those with diabetes and high normal serum K‚Äã+ levels. Assess SCr and K‚Äã+ after a few days, then regularly. |
| **enalapril** (Vasotec, Enalapril, other generics) | Initial: 2.5 mg BID POTarget in HF: 10 mg BID | Dry cough, hyperkalemia, angioedema (unusual).Can precipitate renal failure in patients with renovascular disease, volume depletion or in those receiving NSAIDs. | Marked increase in serum K‚Äã+ in patients receiving K‚Äã+ supplements and/or K‚Äã+-sparing diuretics.Reduced hypotensive effect and increased risk of renal dysfunction with NSAIDs.Elevated Li‚Äã+ levels (potential toxicity). | Use lower (i.e., 50%) initial doses in patients taking diuretics (increased risk of hypotension with hypovolemia).Hyperkalemia usually occurs only in patients taking K‚Äã+ supplements or drugs that cause K‚Äã+ retention, patients with renal impairment or those with diabetes and high normal serum K‚Äã+ levels. Assess SCr and K‚Äã+ after a few days, then regularly. |
| **fosinopril** (generics) | Initial: 10 mg daily POTarget: 20‚Äì40 mg once daily | Dry cough, hyperkalemia, angioedema (unusual).Can precipitate renal failure in patients with renovascular disease, volume depletion or in those receiving NSAIDs. | Marked increase in serum K‚Äã+ in patients receiving K‚Äã+ supplements and/or K‚Äã+-sparing diuretics.Reduced hypotensive effect and increased risk of renal dysfunction with NSAIDs.Elevated Li‚Äã+ levels (potential toxicity). | Use lower (i.e., 50%) initial doses in patients taking diuretics (increased risk of hypotension with hypovolemia).Hyperkalemia usually occurs only in patients taking K‚Äã+ supplements or drugs that cause K‚Äã+ retention, patients with renal impairment or those with diabetes and high normal serum K‚Äã+ levels. Assess SCr and K‚Äã+ after a few days, then regularly. |
| **lisinopril** (Prinivil, Zestril, generics) | Initial: 2.5 mg daily POTarget: 35‚Äì40 mg once daily | Dry cough, hyperkalemia, angioedema (unusual).Can precipitate renal failure in patients with renovascular disease, volume depletion or in those receiving NSAIDs. | Marked increase in serum K‚Äã+ in patients receiving K‚Äã+ supplements and/or K‚Äã+-sparing diuretics.Reduced hypotensive effect and increased risk of renal dysfunction with NSAIDs.Elevated Li‚Äã+ levels (potential toxicity). | Use lower (i.e., 50%) initial doses in patients taking diuretics (increased risk of hypotension with hypovolemia).Hyperkalemia usually occurs only in patients taking K‚Äã+ supplements or drugs that cause K‚Äã+ retention, patients with renal impairment or those with diabetes and high normal serum K‚Äã+ levels. Assess SCr and K‚Äã+ after a few days, then regularly. |
| **perindopril** (Coversyl, Perindopril Erbumine, other generics) | Initial: 2 mg daily POTarget for CAD: 8 mg daily | Dry cough, hyperkalemia, angioedema (unusual).Can precipitate renal failure in patients with renovascular disease, volume depletion or in those receiving NSAIDs. | Marked increase in serum K‚Äã+ in patients receiving K‚Äã+ supplements and/or K‚Äã+-sparing diuretics.Reduced hypotensive effect and increased risk of renal dysfunction with NSAIDs.Elevated Li‚Äã+ levels (potential toxicity). | Use lower (i.e., 50%) initial doses in patients taking diuretics (increased risk of hypotension with hypovolemia).Hyperkalemia usually occurs only in patients taking K‚Äã+ supplements or drugs that cause K‚Äã+ retention, patients with renal impairment or those with diabetes and high normal serum K‚Äã+ levels. Assess SCr and K‚Äã+ after a few days, then regularly. |
| **quinapril** (Accupril, generics) | Initial: 5 mg daily POTarget: 20‚Äì40 mg BID | Dry cough, hyperkalemia, angioedema (unusual).Can precipitate renal failure in patients with renovascular disease, volume depletion or in those receiving NSAIDs. | Marked increase in serum K‚Äã+ in patients receiving K‚Äã+ supplements and/or K‚Äã+-sparing diuretics.Reduced hypotensive effect and increased risk of renal dysfunction with NSAIDs.Elevated Li‚Äã+ levels (potential toxicity). | Use lower (i.e., 50%) initial doses in patients taking diuretics (increased risk of hypotension with hypovolemia).Hyperkalemia usually occurs only in patients taking K‚Äã+ supplements or drugs that cause K‚Äã+ retention, patients with renal impairment or those with diabetes and high normal serum K‚Äã+ levels. Assess SCr and K‚Äã+ after a few days, then regularly. |
| **ramipril** (Altace, Ramipril, other generics) | Initial: 2.5 mg daily POTarget: 5 mg BID or 10 mg daily | Dry cough, hyperkalemia, angioedema (unusual).Can precipitate renal failure in patients with renovascular disease, volume depletion or in those receiving NSAIDs. | Marked increase in serum K‚Äã+ in patients receiving K‚Äã+ supplements and/or K‚Äã+-sparing diuretics.Reduced hypotensive effect and increased risk of renal dysfunction with NSAIDs.Elevated Li‚Äã+ levels (potential toxicity). | Use lower (i.e., 50%) initial doses in patients taking diuretics (increased risk of hypotension with hypovolemia).Hyperkalemia usually occurs only in patients taking K‚Äã+ supplements or drugs that cause K‚Äã+ retention, patients with renal impairment or those with diabetes and high normal serum K‚Äã+ levels. Assess SCr and K‚Äã+ after a few days, then regularly. |
| **trandolapril** (Mavik, generics) | Initial: 1 mg daily POTarget: 4 mg daily | Dry cough, hyperkalemia, angioedema (unusual).Can precipitate renal failure in patients with renovascular disease, volume depletion or in those receiving NSAIDs. | Marked increase in serum K‚Äã+ in patients receiving K‚Äã+ supplements and/or K‚Äã+-sparing diuretics.Reduced hypotensive effect and increased risk of renal dysfunction with NSAIDs.Elevated Li‚Äã+ levels (potential toxicity). | Use lower (i.e., 50%) initial doses in patients taking diuretics (increased risk of hypotension with hypovolemia).Hyperkalemia usually occurs only in patients taking K‚Äã+ supplements or drugs that cause K‚Äã+ retention, patients with renal impairment or those with diabetes and high normal serum K‚Äã+ levels. Assess SCr and K‚Äã+ after a few days, then regularly. |
| **candesartan** (Atacand, Candesartan, other generics) | Initial: 4 or 8 mg daily POTarget in HF: 32 mg once daily | Hyperkalemia.Can precipitate renal failure in susceptible patients (bilateral renovascular disease, those with volume depletion or with concurrent NSAID use).Angioedema has been reported, but a causal association has not been established. | Marked increase in serum K‚Äã+ in patients receiving K‚Äã+ supplements and/or K‚Äã+-sparing diuretics. May elevate Li‚Äã+ levels (potential toxicity).Caution with NSAIDs (see Adverse Effects). | Use lower (i.e., 50%) initial doses in patients on diuretics (increased risk of hypotension with hypovolemia).Hyperkalemia usually occurs only in patients taking K‚Äã+ supplements or drugs that cause K‚Äã+ retention, those with renal impairment or with diabetes and high serum K‚Äã+ levels. Assess SCr and K‚Äã+ after a few days, then regularly. |
| **losartan** (Cozaar, Losartan, other generics) | Initial: 50 mg daily POTarget in HF: 150 mg daily | Hyperkalemia.Can precipitate renal failure in susceptible patients (bilateral renovascular disease, those with volume depletion or with concurrent NSAID use).Angioedema has been reported, but a causal association has not been established. | Marked increase in serum K‚Äã+ in patients receiving K‚Äã+ supplements and/or K‚Äã+-sparing diuretics. May elevate Li‚Äã+ levels (potential toxicity). | Use lower (i.e., 50%) initial doses in patients on diuretics (increased risk of hypotension with hypovolemia).Hyperkalemia usually occurs only in patients taking K‚Äã+ supplements or drugs that cause K‚Äã+ retention, those with renal impairment or with diabetes and high serum K‚Äã+ levels. Assess SCr and K‚Äã+ after a few days, then regularly. |
| **valsartan** (Diovan, generics) | Initial: 20 mg BID POTarget:‚Äã[31] 160 mg BID | Hyperkalemia.Can precipitate renal failure in susceptible patients (bilateral renovascular disease, those with volume depletion or with concurrent NSAID use).Angioedema has been reported, but a causal association has not been established. | Marked increase in serum K‚Äã+ in patients receiving K‚Äã+ supplements and/or K‚Äã+-sparing diuretics. May elevate Li‚Äã+ levels (potential toxicity). | Use lower (i.e., 50%) initial doses in patients on diuretics (increased risk of hypotension with hypovolemia).Hyperkalemia usually occurs only in patients taking K‚Äã+ supplements or drugs that cause K‚Äã+ retention, those with renal impairment or with diabetes and high serum K‚Äã+ levels. Assess SCr and K‚Äã+ after a few days, then regularly. |
| **ASA** (Aspirin, generics) | 80‚Äì325 mg daily PO | Nausea, vomiting, GI hemorrhage, tinnitus, vertigo, hypersensitivity. | Increased risk of bleeding when antiplatelets are given with anticoagulants, e.g., warfarin. Caution with NSAIDs. | Low-dose therapy (75‚Äì100 mg) is as effective as higher doses (300‚Äì325 mg). |
| **clopidogrel** (Plavix, Clopidogrel, other generics) | 75 mg daily PO | Rash, purpura, diarrhea, bleeding. | Caution with NSAIDs. PPI use may reduce clopidogrel efficacy. | Consider an initial dose of 150 mg daily PO √ó 6 days in STEMI and NSTEMI patients after PCI. |
| **prasugrel** (generics) | 10 mg daily PO | Increased risk of bleeding, rash. | Caution with NSAIDs. | Caution in patients >75 y, body weight <60 kg. Consider 5 mg daily if available. Contraindicated if history of ischemic stroke. |
| **ticagrelor** (Brilinta) | 90 mg BID PO‚â•1 y post‚ÄìMI: 60 mg BID PO | Increased risk of bleeding, bradycardia, headache, nausea, transient dyspnea (>13%). | Caution with NSAIDs. Avoid strong CYP3A4 inhibitors, e.g., clarithromycin. Digoxin level increased. | Reversible increase in SCr or uric acid in some patients. |
| **atenolol** (Tenormin, Atenolol, other generics) | Initial: 50 mg daily POUsual: 100 mg daily | Fatigue, bradycardia, reduced exercise capacity, headache, impotence, vivid dreams.Less common: hyperglycemia, depression, heart failure, heart block. | Bradycardia with digoxin or nondihydropyridine CCBs.Cardiodepressant effects with nondihydropyridine CCBs, antiarrhythmics, anesthetics. | Start with low-dose and increase at weekly intervals to maintain heart rate <70 bpm.Contraindications: heart rate <50‚Äì60 bpm, systolic BP <90‚Äì100 mmHg, severe heart failure, cardiogenic shock, severe reactive airway disease, second- or third-degree AV block. |
| **bisoprolol** (Bisoprolol, other generics) | Initial: 2.5 mg daily POUsual: 10 mg daily | Fatigue, bradycardia, reduced exercise capacity, headache, impotence, vivid dreams.Less common: hyperglycemia, depression, heart failure, heart block. | Bradycardia with digoxin or nondihydropyridine CCBs.Cardiodepressant effects with nondihydropyridine CCBs, antiarrhythmics, anesthetics. | Start with low-dose and increase at weekly intervals to maintain heart rate <70 bpm.Contraindications: heart rate <50‚Äì60 bpm, systolic BP <90‚Äì100 mmHg, severe heart failure, cardiogenic shock, severe reactive airway disease, second- or third-degree AV block. |
| **metoprolol** (Lopresor, Metoprolol, other generics) | Initial: 50 mg daily POUsual: 200 mg dailyIR: give in 2 divided dosesSR: give once daily | Fatigue, bradycardia, reduced exercise capacity, headache, impotence, vivid dreams.Less common: hyperglycemia, depression, heart failure, heart block. | Bradycardia with digoxin or nondihydropyridine CCBs.Cardiodepressant effects with nondihydropyridine CCBs, antiarrhythmics, anesthetics. CYP2D6 inhibitors increase levels of propranolol and metoprolol. | Start with low-dose and increase at weekly intervals to maintain heart rate <70 bpm.Contraindications: heart rate <50‚Äì60 bpm, systolic BP <90‚Äì100 mmHg, severe heart failure, cardiogenic shock, severe reactive airway disease, second- or third-degree AV block. |
| **acebutolol** (generics) | Initial: 100‚Äì200 mg BID POUsual: 400 mg BID | Fatigue, bradycardia, reduced exercise capacity, headache, impotence, vivid dreams.Less common: hyperglycemia, depression, heart failure, heart block. | Bradycardia with digoxin or nondihydropyridine CCBs.Cardiodepressant effects with nondihydropyridine CCBs, antiarrhythmics, anesthetics. | Start with low-dose and increase at weekly intervals to maintain heart rate <70 bpm.Contraindications: heart rate <50‚Äì60 bpm, systolic BP <90‚Äì100 mmHg, severe heart failure, cardiogenic shock, severe reactive airway disease, second- or third-degree AV block.Agents with ISA have less effect on resting heart rate than those without ISA. |
| **carvedilol** (Carvedilol, other generics) | Initial: 3.125 mg BID POUsual: 25 mg BID | Fatigue, bradycardia, reduced exercise capacity, headache, impotence, vivid dreams.Less common: hyperglycemia, depression, heart failure, heart block.Edema, dizziness, nasal congestion and postural hypotension due to alpha1 antagonism. | Bradycardia with digoxin or nondihydropyridine CCBs.Cardiodepressant effects with nondihydropyridine CCBs, antiarrhythmics, anesthetics. | Start with low-dose and increase at weekly intervals to maintain heart rate <70 bpm.Contraindications: heart rate <50‚Äì60 bpm, systolic BP <90‚Äì100 mmHg, severe heart failure, cardiogenic shock, severe reactive airway disease, second- or third-degree AV block. |
| **atorvastatin** (Lipitor, Atorvastatin, other generics) | Initial: 10 or 20 mg daily POMaximum: 80 mg/day Once daily with or without meals | GI disturbances, sleep disturbances, headache, rash, myalgia (with and without increased CK levels), increased CK and aminotransferase levels (reversible), myopathy, rhabdomyolysis (rare). | CYP3A4 inhibitors, e.g., amiodarone, cyclosporine, macrolides, protease inhibitors, gemfibrozil, grapefruit juice, azole antifungals, verapamil: increased serum levels of atorvastatin, lovastatin and simvastatin. | Start with 40 mg/day if the desired reduction in LDL-C is >45%.In patients experiencing an ST-elevation myocardial infarction, a starting dose of 80 mg daily has been recommended.‚Äã[10]Maximum response is usually evident within 4 wk. |
| **fluvastatin** (Lescol, generics) | Initial: 20 or 40 mg daily POMaximum: 80 mg/day Once daily with or without meals | GI disturbances, sleep disturbances, headache, rash, myalgia (with and without increased CK levels), increased CK and aminotransferase levels (reversible), myopathy, rhabdomyolysis (rare). | Fluconazole inhibits the metabolism and increases serum levels of fluvastatin. | Start with 40 mg/day if the desired reduction in LDL-C is >25%. |
| **lovastatin** (Lovastatin, other generics) | Initial: 20 mg daily POMaximum: 80 mg/dayTake with the evening meal | GI disturbances, sleep disturbances, headache, rash, myalgia (with and without increased CK levels), increased CK and aminotransferase levels (reversible), myopathy, rhabdomyolysis (rare). | CYP3A4 inhibitors, e.g., amiodarone, cyclosporine, macrolides, protease inhibitors, gemfibrozil, grapefruit juice, azole antifungals, verapamil: increased serum levels of atorvastatin, lovastatin and simvastatin. |  |
| **pravastatin** (Pravachol, Pravastatin, generics) | Initial: 20 mg daily POMaximum: 80 mg/dayTake at bedtime | GI disturbances, sleep disturbances, headache, rash, myalgia (with and without increased CK levels), increased CK and aminotransferase levels (reversible), myopathy, rhabdomyolysis (rare). | Low potential for drug interactions (not metabolized by CYP450 isozymes). |  |
| **rosuvastatin** (Crestor, generics) | 10‚Äì40 mg daily PO | GI disturbances, sleep disturbances, headache, rash, myalgia (with and without increased CK levels), increased CK and aminotransferase levels (reversible), myopathy, rhabdomyolysis (rare). | May increase INR in patients taking warfarin. |  |
| **simvastatin** (Zocor, generics) | 10‚Äì40 mg daily POTake with the evening meal | GI disturbances, sleep disturbances, headache, rash, myalgia (with and without increased CK levels), increased CK and aminotransferase levels (reversible), myopathy, rhabdomyolysis (rare). | CYP3A4 inhibitors, e.g., amiodarone, cyclosporine, macrolides, protease inhibitors, gemfibrozil, grapefruit juice, azole antifungals, verapamil: increased serum levels of atorvastatin, lovastatin and simvastatin. |  |
| **eplerenone** (Inspra, generics) | Initial: 25 mg daily or every 2 days POTarget: 50 mg daily | Hyperkalemia, dehydration, dizziness, diarrhea, nausea. | ACE inhibitors, ARBs, potassium supplements: hyperkalemia.NSAIDs: reduced diuretic effect, worsening renal function, hyperkalemia.Strong inhibitors/inducers of CYP3A4. | Monitor SCr and K‚Äã+ 3 and 7 days after initiating or titrating the dose. Repeat every 1‚Äì3 months once stable. |
| **spironolactone** (Aldactone, generics) | Initial: 12.5 mg daily or every 2 days POTarget (for mortality benefit): 25‚Äì50 mg/day | Hyperkalemia, dehydration, nausea, gynecomastia (usually reversible upon discontinuation). | ACE inhibitors, ARBs, potassium supplements: hyperkalemia.NSAIDs: reduced diuretic effect, worsening renal function, hyperkalemia. | Monitor SCr and K‚Äã+ 3 and 7 days after initiating or titrating the dose. Repeat every 1‚Äì3 months once stable. |


**ü´ò Renal Monitoring - Monitor kidney function when using this medication**

<!-- AI description pending for: images/kidney.gif -->

angiotensin-converting enzyme

angiotensin receptor blocker

atrioventricular

coronary artery disease

calcium channel blocker

creatine kinase

gastrointestinal

heart failure

International Normalized Ratio

immediate release

intrinsic sympathomimetic activity

left ventricular

myocardial infarction

nonsteroidal anti-inflammatory drug

non‚ÄìST elevation myocardial infarction

percutaneous coronary intervention

proton pump inhibitor

serum creatinine

sustained release

ST elevation myocardial infarction

#### Suggested Readings

Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;130(25):2354-94.

Mehta SR, Bainey KR, Cantor WJ et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy. *Can J Cardiol *2018;34(3):214-33.

O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;127(4):529-55. 

#### References


---

## Source Information

**Original Source:** [https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/post-myocardial_infarction](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/post-myocardial_infarction)  
**Content Type:** therapeutic_choices  
**Processed:** 2025-05-29 07:19 UTC  
**Source System:** Canadian Pharmacists Association (CPS)

### How to Cite
> Canadian Pharmacists Association. *post-myocardial_infarction*. 
> CPS Online. Retrieved 2025-05-29 07:19 UTC from https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/post-myocardial_infarction


```

*Note: This document was processed using automated tools. Always refer to the original source for the most up-to-date information.*

---
*Document processed with CPS Pipeline v1.0 ‚Ä¢ [Source URL](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/post-myocardial_infarction)*
